The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy

Current Therapeutic Research - Clinical and Experimental

Volumn 76, Issue , 2014, Pages 76-83

  Galanis, Taki ^a   Keiffer, Gina ^a   Merli, Geno ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anticoagulation; Apixaban; Dabigatran etexilate; Deep vein thrombosis; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ARTICLE; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; VENOUS THROMBOEMBOLISM;

EID: 84908318299     PISSN: 0011393X     EISSN: 18790313     Source Type: Journal    
DOI: 10.1016/j.curtheres.2014.06.002     Document Type: Review

References (28)

1. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124(14):1573-1579. 10.1161/CIRCULATIONAHA.111.029017.
2. van Ryn J., Stangier J., Haertter S., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103(6):1116-1127. 10.1160/TH09-11-0758.
3. Funk D.M. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012, 2012:460-465. 10.1182/asheducation-2012.1.460.
4. Ogata K., Mendell-Harary J., Tachibana M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50(7):743-753. 10.1177/0091270009351883.
5. Bauersachs R., Berkowitz S.D., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363(26):2499-2510. EINSTEIN Investigators. 10.1056/NEJMoa1007903.
6. Buller H.R., Prins M.H., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366(14):1287-1297. EINSTEIN-PE Investigators. 10.1056/NEJMoa1113572.
7. Prins M.H., Lensing A.W., Bauersachs R., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013, 11(1):21-9560-11-21. 10.1186/1477-9560-11-21.
8. Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013, 10.1056/NEJMoa1302507.
9. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361(24):2342-2352. 10.1056/NEJMoa0906598.
10. Schulman S., Kakkar A.K., Goldhaber S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014, 129(7):764-772. 10.1161/CIRCULATIONAHA.113.004450.
11. Buller H.R., Decousus H., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013, 369(15):1406-1415. Hokusai-VTE Investigators. 10.1056/NEJMoa1306638.
12. Agnelli G., Buller H.R., Cohen A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368(8):699-708. 10.1056/NEJMoa1207541.
13. Schulman S., Kearon C., Kakkar A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368(8):709-718. 10.1056/NEJMoa1113697.
14. Kearon C., Akl E.A., Comerota A.J., et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e419S-e4194. 10.1378/chest.11-2301.
15. Lega J.C., Bertoletti L., Gremillet C., Boissier C., Mismetti P., Laporte S. Consistency of safety profile of new oral anticoagulants in patients with renal failure. J Thromb Haemost 2014, 12(3):337-343. 10.1111/jth.12486.
16. Ghuysen A., Ghaye B., Willems V., et al. Computed tomographic pulmonary angiography and prognostic significance in patients with acute pulmonary embolism. Thorax 2005, 60(11):956-961. doi: thx.2005.040873 [pii].
17. Soares T.H., de Bastos M., de Carvalho B.V., et al. Prognostic value of computed tomographic pulmonary angiography and the pulmonary embolism severity index in patients with acute pulmonary embolism. Blood Coagul Fibrinolysis 2013, 24(1):64-70. 10.1097/MBC.0b013e32835a72c2.
18. van der Meer R.W., Pattynama P.M., van Strijen M.J., et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: Prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005, 235(3):798-803. doi:2353040593 [pii].
19. Wu A.S., Pezzullo J.A., Cronan J.J., Hou D.D., Mayo-Smith W.W. CT pulmonary angiography: Quantification of pulmonary embolus as a predictor of patient outcome-initial experience. Radiology 2004, 230(3):831-835. 10.1148/radiol.2303030083.
20. Jaff M.R., McMurtry M.S., Archer S.L., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the American Heart Association. Circulation 2011, 123(16):1788-1830. 10.1161/CIR.0b013e318214914f.
21. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365(8):699-708. 10.1056/NEJMoa1105819.
22. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366(1):9-19. 10.1056/NEJMoa1112277.
23. Oldgren J., Budaj A., Granger C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011, 32(22):2781-2789. 10.1093/eurheartj/ehr113.
24. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151. 10.1056/NEJMoa0905561.
25. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172(5):397-402. 10.1001/archinternmed.2011.1666.
26. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992. 10.1056/NEJMoa1107039.
27. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891. 10.1056/NEJMoa1009638.
28. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014, 383(9921):955-962. 10.1016/S0140-6736(13)62343-0.